Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Arsenic Trioxide→

Arsenic Trioxide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1327-53-3
Molecular formula
As2O3
Molecular weight
197.841 g/mol
Drug class
Antineoplastic differentiating agentarsenical cytotoxic drug
Mechanism of action
In acute promyelocytic leukaemia (APL), arsenic trioxide promotes degradation of the PML-RARα fusion oncoprotein and induces differentiation and apoptosis of abnormal promyelocytes. Additional cellular effects contribute to antineoplastic activity.
Indications / reported uses
  • Treatment of newly diagnosed low-risk acute promyelocytic leukaemia (APL) in combination with tretinoin
  • Treatment of relapsed or refractory APL in product-specific regimens under specialist haematology care

Sources: US DailyMed — TRISENOX (arsenic trioxide) · NCI Drug Dictionary — Arsenic trioxide · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Antineoplastic differentiating agent; arsenical cytotoxic drug

Mechanism of action

In acute promyelocytic leukaemia (APL), arsenic trioxide promotes degradation of the PML-RARα fusion oncoprotein and induces differentiation and apoptosis of abnormal promyelocytes. Additional cellular effects contribute to antineoplastic activity.

General use cases

  • Treatment of newly diagnosed low-risk acute promyelocytic leukaemia (APL) in combination with tretinoin
  • Treatment of relapsed or refractory APL in product-specific regimens under specialist haematology care

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Arsenic Trioxide Environmental Risk Assessment (ERA) (the Arsenic Trioxide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.